✦ LIBER ✦

Clinical benefit in NSCLC: the evidence for gefitinib (‘Iressa’, ZD1839)

✍ Scribed by Lynch, Thomas

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

I-97. Clinical benefit in NSCLC: The evi

✍ Lynch, Thomas 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 123 KB

New perspectives in the management of no

✍ C. Manegold 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 280 KB

P-617 Gefitinib (ZD 1839, Iressa) as a l

✍ Haringhuizen, Annebeth; Vaessen, Heleen F.R.; Baas, Paul; van Zandwijk, Nico 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 189 KB

P-620 Gefitinib (‘Iressa’, ZD1839) monot

✍ Park, Jinny; Park, Byeong-Bae; Lee, Se-Hoon; Park, Se Hoon; Lee, Kyung-Eun; Lee, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 174 KB

O-243 Clinical benefits in patients with

✍ Janne, Pasi A.; Gurubhagavatula, Sarada; Lucca, Joan; Ostler, Patricia; Skarin, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 193 KB

O-45 Drug sensitivity test (in vitro gro

✍ Takao, Motoshi; Inoue, Kentaro; Watanabe, Fumiaki; Tarukawa, Tomohito; Kaneda, M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 182 KB